Tu Song-Tao, Zhou Yu-Lan, Li Fei
Center of Hematology, The First Affiliated Hospital of Nanchang University;Nanchang 330006, Jiangxi Province, China,Institute of Hematology, Academy of Clinical Medicine of Jiangxi Province;Nanchang 330006, Jiangxi Province, China,Institute of Lymphoma of Nanchang University, Nanchang 330006, Jiangxi Province, China.
Center of Hematology, The First Affiliated Hospital of Nanchang University;Nanchang 330006, Jiangxi Province, China,Institute of Hematology, Academy of Clinical Medicine of Jiangxi Province;Nanchang 330006, Jiangxi Province, China,Institute of Lymphoma of Nanchang University, Nanchang 330006, Jiangxi Province, China,E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023 Feb;31(1):301-305. doi: 10.19746/j.cnki.issn.1009-2137.2023.01.048.
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory clinical syndrome of uncontrolled immune response which results in hypercytokinemia due to underlying primary or secondary immune defect. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only cure therapy for primary HLH and recurrent/refractory hemophagocytic lymphohistiocytosis. Compared with children HLH, adult HLH is a much more heterogeneous syndrome requiring a more individualized protocol depending on the underlying trigger, disease severity and genetic background. At present, there remain controversies in various aspects including indications of haematopoietic cell transplantation (HCT), conditioning regimen, efficacy and prognosis. This article will review the recent advances of allo-HSCT in the treatment of adult HLH based on the above issues.